Comparison of rArt v 1-based sublingual and subcutaneous immunotherapy in a murine model of asthma
Mugwort-allergic patients frequently experience severe respiratory allergies due to sensitization to the major allergen Art v 1, with allergen-specific immunotherapy (ASIT) as the only causal treatment to halt disease progression. This study evaluated the effects of subcutaneous (SCIT) and sublingua...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Research
2025
|
| Subjects: | |
| Online Access: | http://umpir.ump.edu.my/id/eprint/45117/ http://umpir.ump.edu.my/id/eprint/45117/1/Comparison%20of%20rArt%20v%201-based%20sublingual%20and%20subcutaneous%20immunotherapy.pdf |
| Summary: | Mugwort-allergic patients frequently experience severe respiratory allergies due to sensitization to the major allergen Art v 1, with allergen-specific immunotherapy (ASIT) as the only causal treatment to halt disease progression. This study evaluated the effects of subcutaneous (SCIT) and sublingual (SLIT) ASIT with purified recombinant Art v 1 (rArt v 1) in a murine model of mugwort pollen of asthma. BALB/c mice were sensitized with Artemisia vulgaris pollen extract and treated with either rArt v 1-based SCIT adjuvanted with Montanide ISA-51, rArt v 1-based SLIT, an extract-based commercial SLIT vaccine, or PBS. Both rArt v 1-based SCIT and SLIT improved lung pathology and reduced airway reactivity following allergen challenge, with rArt v 1-based SCIT inducing Th1-polarized immune responses marked by increased IFN-γ production and rArt v 1-specific IgG1/IgG2a, while SLIT induced stronger mucosal IgA responses. These findings highlight the therapeutic potential of rArt v 1-based ASIT for mugwort allergy. |
|---|